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Abstract: Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) represents
an important subset of S. aureus infection and correlates with poor clinical outcomes. MRSA isolates
from patients with PB differ significantly from those of resolving bacteremia (RB) with regard to
several in vitro phenotypic and genotypic profiles. For instance, PB strains exhibit less susceptibility
to cationic host defense peptides and vancomycin (VAN) killing under in vivo-like conditions,
greater damage to endothelial cells, thicker biofilm formation, altered growth rates, early activation
of many global virulence regulons (e.g., sigB, sarA, sae and agr) and higher expression of purine
biosynthesis genes (e.g., purF) than RB strains. Importantly, PB strains are significantly more resistant
to VAN treatment in experimental infective endocarditis as compared to RB strains, despite similar
VAN minimum inhibitory concentrations (MICs) in vitro. Here, we review relevant phenotypic
and genotypic characteristics related to the PB outcome. These and future insights may improve
our understanding of the specific mechanism(s) contributing to the PB outcome, and aid in the
development of novel therapeutic and preventative measures against this life-threatening infection.
Keywords: MRSA; persistence; endovascular infection; phenotype; genotype
1. Introduction
Staphylococcus aureus is a prominent Gram-positive bacteria that can cause a wide spectrum
of diseases, ranging from minor skin and skin structure infections to life-threatening diseases
(e.g., bacteremia and endocarditis) [1]. In addition, S. aureus is a predominant cause of bacteremia and
has emerged as a common entity associated with significant morbidity, complications, and mortality [2].
The emergence of methicillin-resistant S. aureus (MRSA) has further complicated the management of
patients with staphylococcal bacteremia, increasing duration of hospital stay and cost, while decreasing
the therapeutic efficacy of available antimicrobial agents [3–6]. Persistent MRSA bacteremia (PB; defined
as ≥7 days of MRSA-positive blood cultures, despite appropriate antibiotic treatment) representing
15–30% of MRSA bacteremia, is especially relevant to endovascular infection and associated with high
rates of morbidity and mortality (15–40%) [2,7,8]. Importantly, many PB isolates appear to be susceptible
in vitro to existing gold-standard anti-MRSA antibiotics such as vancomycin (VAN) and daptomycin
(DAP), based upon the Clinical and Laboratory Standards Institute (CLSI) breakpoints [7–10]. To date,
we and other investigators have demonstrated specific phenotypic and genotypic features of MRSA
may play important roles in the PB outcome [7,9,11–14].
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In this review, we provide a summary overview of what is known about the specific genotypic
and phenotypic characteristics of MRSA isolates related to the PB outcome, focusing on two distinct
but interrelated facets: (1) Pathogen-drug interactions; and (2) pathogen-host interactions. In addition,
salvage therapy and potential new targets to combat life-threatening MRSA outcomes are considered.
2. Genotypic Characteristics of MRSA Persistent Bacteremia
2.1. Standard Molecular Typing
Investigations have revealed differences between PB vs. resolving MRSA bacteremia isolates
(RB; defined as initial bacteremia resolved within four days of therapy) in genotypic profiles, including
pulsed-field gel electrophoresis (PFGE), multi-locus sequence typing (MLST), staphylococcal protein A
(spa) profiles, staphylococcal cassette chromosome mec (SCCmec) and accessory gene regulator (agr)
typing, [7,9,12,15] (Table 1). Currently, PFGE is the most widely used gold standard for molecular
typing of MRSA strains [16]. Fowler et al. reported that over 85% of PB isolates from one institution had
closely related PFGE patterns likely representing a single genetic lineage, while only 44% of RB isolates
shared the same PFGE genotyping [9]. As a DNA fingerprinting technique based upon polymorphisms
within seven housekeeping genes in S. aureus, MLST is used to group S. aureus strains into unique clonal
complexes (CC) [17]. Interestingly, studies focusing on the four most common CC types (e.g., CC5,
CC8, CC30, and CC45) in clinical infection settings revealed that CC5 and CC30 are significantly
associated with hematogenous complications of PB as compared to RB [7,18]. Another complementary
genotyping methodology that appears to be useful in categorizing large S. aureus strain collections is spa
typing. This technique leverages common polymorphisms within this gene locus [19]. Of great interest,
an association trend of spa type 16 (W-G-K-A-K-A-O-M-Q-Q-Q-Q) was found among PB isolates [7,13].
SCCmec elements and unique genomic islands may also benefit the specific characterization of MRSA
clones in epidemiological studies [20]. Among the five major SCCmec classes (types I-V), SCCmec type
II appears to be associated with MRSA isolates from PB patients [7,13]. Furthermore, the agr operon,
a quorum-sensing system in S. aureus, is a key global regulon that controls many critical virulence
pathways in this pathogen [21]. DNA sequence polymorphisms of this locus include four agr groups
(types I-IV) [22]. PB strains more frequently contain polymorphisms in agr groups II and III compared
to RB strains [7,23]. Taken together, these observations suggest that specific genotypic profiles exist
which differentiate PB vs. RB clinical isolates.
Table 1. Genotypic and phenotypic comparison of methicillin-resistant Staphylococcus aureus (MRSA)
isolates from persistent bacteremia (PB) and resolving bacteremia (RB).
Characteristic PB Isolates(Frequency)
RB Isolates
(Frequency) References
Genotypic
Identical PFGE cluster 85% 44% [9]
MLST CC5 (53%),CC30 (21%–48%) CC30 (18%) [7,13,18]
spa type 16 (21%) 16 (18%) [7,13]
SCCmec type II (21%) II (18%) [7,13]
agr type II (68.9%), III (21%) II (27.8%), III (18%) [7,23]
Screen of virulence genes cna (21%), cap8 (21%),tst-1 (21%)
sdrD (47%), sdrE (47%),
cap5 (21%), pvl (56%) [7,14,18]
Prophage 2 1 [24]
Early on-set activation of global
regulons/genes in PB vs. RB agr RNAIII, sigB, sarA, sae, cap5 [15,25,26]
Higher gene expression in PB vs. RB Purine-, amino acid-, carbohydrates-biosynthesis pathway, psms
[25]
unpublished
Lower gene expression in PB vs. RB Histidine biosynthesis pathway genes [25]
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Table 1. Cont.
Characteristic PB Isolates(Frequency)
RB Isolates
(Frequency) References
Phenotypic
Pathogen-Drug interactions (PB vs. RB)
Survival with VAN exposure > [27]
VAN binding < [27]
In vitro growth rate > [25]
Biofilm formation ± sub-MIC VAN
(under static conditions) > [27]
Biofilm formation (under flow
conditions) > [27]
Pathogen-Host interactions (PB vs. RB)
Survival with HDPs exposure > [7,11]
Membrane fluidity > [7,28]
Survival with PMNs exposure > unpublished
Adherence to Fn and Fg > [29]
Fn-FnBPs binding > [29]
EC damage > [30]
α-, δ-hemolysin > [9,12]
VAN effectiveness in an IE model < [7,12,15]
NOTE. PFGE, pulsed-field gel electrophoresis; MLST, multi-locus sequence typing; CC, clonal complex; SCCmec,
staphylococcal cassette chromosomemec; VAN, vancomycin; HDPs, host defense peptides; PMN, polymorphonuclear
leukocytes; Fn, fibronectin; Fg, fibrinogen; EC, endothelial cell; FnBPs, Fn-binding proteins; IE, infective endocarditis;
>, higher in PB vs. RB isolates; <, lower in PB vs. RB isolates.
2.2. Screening of Virulence Genes
It is well-accepted that the presence of key relevant virulent genes contributes to the PB outcome.
Xiong et al. used multiplex polymerase chain reaction (PCR) to assess a panel of strategic 33 virulence
genes, including regulatory-, adhesion-, exotoxin-, anti-phagocytic- and exoenzyme-encoding genes.
They found PB (vs. RB) isolates to have a higher frequency of the collagen-binding protein-encoding
gene (cna), capsular polysaccharide type 8 (cap8) and the toxic shock syndrome toxin-encoding gene
(tst-1). In contrast, the cell-wall associated genes sdrD and sdrE, cap5 and the panton-valentine
leukocidin gene pvl, were significantly over-represented among RB vs. PB strains [7,14,18] (Table 1).
While these results did not evaluate the expression of such genes, these data suggest that the presence
or absence of key virulence genes could be used as a powerful tool to differentiate PB vs. RB isolates.
For instance, the increased presence of adhesion gene, cna, might allow PB strains to exploit specific
anatomic sites (e.g., endothelial substrata, bones) and potentially contribute to colonization and the
persistent outcome. Besides virulence genes, a prophage (size 44.2 kb) inserted in a hypothetical
protein with ostensible function involved in oxidoreduction reactions was found by whole genome
sequencing in a prototype PB strain (300–169, agr-I, SCCmec IV, CC45), but absent in its RB counterpart
(301–188, agr-I, SCCmec IV, CC45) [24]. The impact of prophages on virulence gene expression (e.g., sigB,
hld), biofilm formation, and pathogenesis of staphylococcal infections have been reported [31,32].
For example, the β-hemolysin (hld) converting prophage ϕNM3 located in the S. aureus Newman
chromosome, encodes modulators of innate immune responses (e.g., sea). An S. aureus Newman
variant lacking ϕNM3 displayed organ-specific virulence defects in a murine infection model [32].
Therefore, understanding the specific role of prophage in MRSA pathogenesis overall, and PB outcomes
specifically is needed.
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2.3. Activation of Global Regulons
The impact of global regulators (e.g., agr RNAIII, sigB, sarA and sae) on the transcription of key
virulence genes and therapeutic outcomes in vivo, including the infective endocarditis (IE) model,
has been previously reported [25,26,33]. In S. aureus, the agr quorum-sensing system is critical for
the regulation of many virulence genes primarily through RNA III [12,21]. The sigma factor, SigB,
represents a powerful regulator to environmental stress, especially in response to antibiotics, and to
impact the expression of multiple virulence genes and global regulators, including sarA [34]. sarA has
been reported to be involved in controlling many virulence genes, e.g., hla [21]. The sae two-component
system was also found to be a key element in the governing the staphylococcal virulon e.g., toxic shock
syndrome toxin 1 [33]. Of note, PB strains exhibited early agr RNAIII activation, which is significantly
associated with persistence, despite VAN treatment in IE models [12,15]. Interestingly, strategic agr
deletion in PB strains did not impact persistent outcomes [12]. These data underscored the notion that
differential overall activation of the agr locus is not causal in PB outcomes. Therefore, factors beyond
agr likely play important roles in PB. Recent findings revealed early on-set activation of a cadre of
critical S. aureus global regulators, including sigB, sarA and sae as well as key downstream structural
genes such as cap5, also differentiate PB vs. RB strains [25]. These genetic observations have been
further verified in a representative PB (300–169) and RB (301–188) strain pair by using an in vitro cDNA
microarray [25]. Importantly, these data showed that the expression of key genes involved in metabolic
pathways, including nucleotide, amino acid, and carbohydrate biosynthesis was approximately 2-fold
higher in PB vs. RB strains, while RB (vs. PB strains) had ≥2-fold higher expression of histidine
biosynthesis and proteolysis-encoding genes [25] (Table 1). Remarkably, the significantly higher
transcription of multiple purine biosynthesis pathway genes (e.g., purF, purM, purN, purH and purl),
crucial for cell growth via DNA and RNA synthesis, was observed in PB vs. RB strains [25,35,36].
Consistently, faster growth in PB vs. RB strains in vitro has been seen in artificial media growth curve
assays [25]. The activation of those global regulators (e.g., sigB, sarA, agr, and sae) and the downstream
structure gene cap5 are growth-phase-dependent [33,37–39], thus altered growth kinetics in distinct
tissue contexts may impact the early on-set activation of global regulators in PB vs. RB strains [25] that
are influenced by quorum-sensing.
3. Phenotypic Characteristics of MRSA Persistent Bacteremia
3.1. Pathogen-Drug Interactions
3.1.1. VAN Susceptibility In Vitro vs. In Vivo
VAN is established as the first-line treatment of most MRSA infections [6], as most MRSA
strains are susceptible to VAN in vitro (MIC range 0.5–2.0 µg/mL) based on CLSI breakpoints.
However, VAN treatment failures, especially in endovascular syndromes—due to MRSA having
a VAN-susceptible phenotype in vitro—occur frequently. This persistent outcome represents a
unique and important variant of traditional antibiotic resistance, and emphasizes the urgent need
to better understand the specific mechanisms of this syndrome for successful treatment of such
persistent infections.
3.1.2. VAN-Killing Activity and Affinity for MRSA
Previous studies demonstrated that PB strains exhibited significantly higher survival than their RB
counterparts on exposure to VAN under conditions of MRSA density and VAN concentrations
(15 µg/mL), simulating the in vivo infection [27]. In this regard, PB strains recapitulated less
susceptibility to VAN-induced bloodstream clearance vs. RB strains, which is consistent with the
clinical setting [9] (Table 1). Several potential factors may contribute to this phenomenon: Firstly, it is
known that VAN binds to bacterial cell-wall peptidoglycan precursor (e.g., D-Ala-D-Ala residues) to
achieve its antibiotic effect [40,41]. The alteration of major cell wall components, such as wall teichoic
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acids and lipoteichoic acids might influence the affinity for VAN binding [41]. Abdelhady et al. found
that VAN binds significantly less to PB isolates than matched RB isolates [27]. Therefore, higher
survival to VAN exposure might be due to less VAN-binding capability. Secondly, as detailed above,
elevated purine biosynthesis in PB strains may drive altered growth kinetics and entry into a stationary
phase earlier than RB strains [25]. As adenosine triphosphate (ATP) levels begin to decrease when
MRSA cells reach the stationary phase, VAN bactericidal activity would, in turn, be expected to
decrease [25,39]. This model is consistent with the rapid initial growth of PB strains, leading to
lower ATP levels and higher survival against VAN exposure, due to faster growth as compared to RB
strains [25,39]. It is also known that a thickened cell wall appears to be associated with reduced VAN
access to its active site, which leads to the reduction of VAN susceptibility [42]. However, no significant
association has been seen between cell wall thickness profiles and PB strains [27].
3.1.3. MRSA Biofilm Formation
It is well-known that biofilm can foster resistance to bacterial clearance mediated by antibiotics
and host immune response, and bacteria protected by biofilm can serve as chronic infective foci [43].
Previous studies demonstrated that PB strains formed significantly thicker biofilm than RB strains under
both static and flow conditions [27]. For instance, Seidl et al. found that, as a group, PB strains exhibited
approximately 1.5-fold higher biofilm formation than matched RB strains under static conditions [11].
Moreover, under flow conditions, a representative PB strain 300–169 formed a thicker confluent
biofilm (average biomass 36 µm3/µm2) than a RB counterpart strain 301–188 (0.02 µm3/µm2) [27].
Since the mechanism(s) of VAN treatment persistence related to VAN-susceptibility (based on CLSI
criteria) in MRSA strains remain unclear, biofilm formation with a sub-MIC of VAN exposure was
also assessed [27,44] (Table 1). Overall, significantly enhanced biofilm formation in response to a
sub-MIC VAN exposure under static conditions only occurs in PB isolates, again suggesting a potential
association with persistent outcomes as antibiotic exposure waxes and wanes during therapy [27,44].
3.2. Pathogen-Host Interactions
3.2.1. Host Defense Peptide (HDP) Susceptibility
Prior to and upon entering the bloodstream, S. aureus must confront the essential defense
mechanisms of the host, especially HDPs [45]. Such primary HDPs, including those of hematopoietic
origin (e.g., neutrophils (hNP-1) and platelets (PMPs)), act in first-line host defense and often provide
rapid and efficient protection against invading blood-borne pathogens, including S. aureus (Table 1;
Figure 1) [45–47]. Previous studies have established that reduced susceptibility to HDPs in vitro
corresponds with enhanced in vivo virulence in S. aureus endovascular infections [11,48]. For example,
compared with RB isolates, PB strains exhibited significantly higher survival to hNP-1 and PMP
exposures in vitro [7,11]. It is known that most HDPs initially target the bacterial cell membrane to
initiate their lethal mechanism(s). Peschel et al. demonstrated that mprF, a lysyl-phosphatidylglycerol
[L-PG] synthase, adds positively-charged lysine to negatively-charged PG molecules embedded in the
staphylococcal cell membrane [49]. This process results in an increased net positive surface charge,
thus reducing the electrostatic affinity of HDPs for the S. aureus cell membrane. In turn, this adaptive S.
aureus response can lead to considerably less susceptibility to HDPs [49]. It is conceivable that such an
immune subversive mechanism only occurs in vivo, contributing to the PB phenomenon during actual
clinical infection. Furthermore, associations between an mprF variant (a single nucleotide mutation
within the mprF gene) and persistent outcomes have been reported, supporting the view that mprF
plays key roles in HDP susceptibility, and thus contributes to persistence [50]. Additionally, it is
known that bacterial membrane fluidity can affect PMP susceptibility [28]. Bayer et al. found cationic
peptide-resistant S. aureus (e.g., tPMP-1-resistant S. aureus) exhibited significantly higher degrees of
membrane fluidity than susceptible counterparts [28]. Likewise, higher cell membrane fluidity was
also found in PB vs. RB strains [7].
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Figure 1. Overview of persistent bacteremia in the context of endovascular infection due to
methicillin-resistant Staphylococcus aureus [6]. EC, endothelial cell; Fn, fibronectin; Fg, fibrinogen; PMN,
neutrophils; VAN, vancomycin.
3.2.2. Survival in the Face of Polymorphonuclear Leukocytes (PMNs)
PMNs provide the first line of cellular innate immunity by phagocytosing and killing
bacteria [46,51]. To evade killing by PMN-mediated host innate immune system, a family of cytolytic
peptides, phenol soluble modulins (psms) can be expressed by S. aureus, which effects the lysis of PMN
prior to or during S. aureus phagocytosis [52]. Consistent with this view, our recent studies have shown
PB strains exhibited significantly higher expression of psms, positively correlating with higher PMN
lysis and survival to PMN bactericidal activity vs. RB strains (our unpublished data). Transcription
of psms is tightly coupled to global quorum-sensing by agr [53]. As we have shown, the significantly
earlier agrA and agr RNAIII activation in PB but not RB isolates may impact this cytotoxic capability of
MRSA strains [12,15]. Taken together, the higher PMN lysis and survival to PMN bactericidal activity
due to increased psm expression via agr in PB vs. RB strains likely contribute to persistent outcomes.
3.2.3. Adherence to Host Endothelial Cells and Substrates
Following avoidance of host defense-mediated killing, S. aureus must bind to host cells and/or
substrate ligands to prevent clearance by the reticuloendothelial system. In endovascular infections
such as IE, S. aureus exploits endothelial cell (EC) adhesion and invasion to cause infection and
subvert host immunity (Table 1; Figure 1) [54]. Predominant adhesins involved in S. aureus EC
adhesion are thought to be staphylococcal cell wall-anchored fibronectin-binding proteins (FnBPs) and
fibrinogen-binding protein A (clumping factor A (ClfA)), which bind to host cell-surfaces through
fibrinogen (Fn) and fibronectin (Fg), respectively [55]. Interestingly, substantially higher adherence
to Fn or Fg in PB isolate groups, as compared to matched RB groups, has been demonstrated [29].
Additionally, PB strains also showed stronger avidity in their binding to Fn and FnBPs, including
higher adhesion force, rupture force and energy of binding vs. RB strains [29]. In contrast, there was no
difference in the capacity of PB vs. RB strain in the overall adherence to ECs [7,11], suggesting specific
ligand signatures as being important for EC exploitation. Overall, the higher capability of adherence
to Fn and Fg or other substrates yet to be determined in PB strains (vs. RB strains) as a phenotypic
feature that participates in the persistent outcome.
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3.2.4. Endothelial Cell Invasion and Damage
After their successful binding, S. aureus can rapidly invade ECs and persist intracellularly
(Table 1; Figure 1) [54]. Intracellular survival, likely in altered metabolic states (e.g., small colony
variants [56,57]) may be an important factor for persistence, relapse or chronicity. These scenarios occur
when internalized S. aureus avoids host immune defenses and effects of many antimicrobial agents [58].
In addition, over the course of long-term infection, S. aureus can cause cell damage to lyse the host cell
and disseminate the infection (Table 1; Figure 1) [54]. In this way, the life-cycle of chronic S. aureus
infection is perpetuated. Interestingly, our recent studies demonstrated no significant difference in
the capacity of EC invasion between PB and RB study strains [30]. However, significantly greater
EC damage in PB vs. RB strains was observed, which may be also associated with VAN treatment
persistent outcomes in the IE model [30]. It is known that hemolysins, including α- (e.g., α-toxin),
β- and δ-hemolysin, produced by S. aureus, are required for metastatic dissemination of infection to
target organs [59]. Interestingly, higher production of α- and δ-hemolysins was found in PB vs. RB
strains [9,12], but not β-hemolysin production [50].
3.2.5. VAN Efficacy in IE Models
In the absence of antibiotics, no significant difference of MRSA densities in the target tissues
(e.g., vegetation, kidney, spleen) in animals infected with PB or RB strains are observed. This finding
is indicative of the view that PB and RB strains exhibited similar intrinsic virulence in the IE
model [7,12,15]. However, antibiotic exposure in vivo reveals how MRSA isolates may adaptively
respond to achieve PB outcomes. For example, VAN therapy resulted in significant reductions of
MRSA densities in all the target tissues in animals infected with RB strains vs. untreated controls.
In contrast, rabbits infected with PB strains exhibited significant resistance to VAN treatment in the IE
model (Table 1) [7,12,15]. Thus, VAN treatment effectiveness in the IE model clearly distinguishes PB
from RB isolates and outcomes.
4. Treatment Strategies for Persistent MRSA Endovascular Infection
VAN and DAP are first-line antibiotics approved by the US Food and Drug Administration for
treatment of MRSA infections [6]. To effectively treat persistent MRSA bacteremia, novel strategies
are necessary, and may involve antibiotic combination therapy. Such treatment strategies might
include VAN + ceftaroline (CPT), DAP + CPT, DAP + trimethoprim/sulfamethoxazole (TMP/SMX),
and TMP/SMX + CPT, etc. [60]. Additionally, several case reports have been published using a protein
synthesis inhibitor (e.g., linezolid) and bactericidal lipoglycopeptide (e.g., telavancin) to successfully
eradicate persistent MRSA bacteremia [61,62]. As detailed above, CPT has been commonly used
in combination with other antibiotics, including VAN and DAP, as salvage therapy, largely due to
potent anti-biofilm activity [63]. By impairing biofilm formation as a key virulence factor in S. aureus,
resistance to environmental stressors such as antimicrobial agents and host immune responses may
also be inhibited [43]. Besides antibiotic combination, alternative strategies include a combination
of small molecule compounds with existing antibiotics. Small molecule compounds that inhibit
bacterial adaptive resistance in PB, alone or as adjunctive therapy combined with specific antibiotics,
could conceivably restore efficacy among antibiotics presently considered ineffective. As a case in point,
it is known that the major global regulator SarA controls many staphylococcal virulence factors and
mediates biofilm formation via repressing core protease production [64]. Our recent studies revealed
that sarA inactivated PB strains become exquisitely susceptible to VAN therapy in IE models [44].
In addition, sarA is now known to be involved in oxacillin (OXA) resistance through regulation of mecA
expression in MRSA PB isolates [65]. This hyper-susceptibility to OXA treatment in the IE model of sarA
mutants in MRSA strain backgrounds was also demonstrated [65]. Thus, sarA activation may serve
important roles in the persistence of MRSA endovascular infections, and has become a new target for
the development of novel therapeutic tools against these life-threatening infections. The combination
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therapy of SarA inhibitors (e.g., SarABI [66]) with cell wall-active antibiotics such as VAN and OXA
could plausibly lead to successful treatment of persistent MRSA infections. In addition, a positive
correlation between purine biosynthesis and the persistent outcomes has been recently reposted [25].
The purine biosynthesis pathway affects the activation of key global regulators (e.g., sigB, sarA, agr and
sae), and VAN therapeutic efficacy in the IE model. Therefore, if selective targeting of these pathways
in MRSA is possible, this approach could represent another new target for treating the persistent MRSA
endovascular infection [25].
5. Conclusions
Investigating critical contributions of virulence factors and their regulation to persistent MRSA
endovascular infection has revealed an overarching theme: No individual virulence determinant
is sufficient to cause a persistent outcome. Furthermore, there is increasing evidence that specific,
multi-variable phenotypic and genotypic signatures differentiate PB from RB in human clinical infection.
Thus, differentiating the genotypic and phenotypic characteristics of MRSA strains and their adaptive
responses in vitro from those that occur in the patient are urgently needed. In this way, discerning
persistent vs. resolving bacteremia might be achieved by identifying biomarkers for predicting
and prospectively intervening to prevent persistent outcomes. These efforts will also deepen our
understanding of pathogen-drug and pathogen-host interactions in all MRSA infections. Continued
studies are needed in these respects, and in novel drug development, to contribute to new and more
effective agents and strategies to meet the challenge of these life-threatening infections.
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